Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GLM044
MIFTS: 39

Glomerular Disease

Categories: Nephrological diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Glomerular Disease

About this section

MalaCards integrated aliases for Glomerular Disease:

Name: Glomerular Disease 58 17

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 32
Orphanet: 58  
Rare renal diseases


External Ids:

UMLS via Orphanet 72 C0268731
Orphanet 58 ORPHA93548
Sources

Summaries for Glomerular Disease

About this section
MalaCards based summary : Glomerular Disease is related to membranoproliferative glomerulonephritis and iga nephropathy 1. An important gene associated with Glomerular Disease is COL4A5 (Collagen Type IV Alpha 5 Chain), and among its related pathways/superpathways are Primary Focal Segmental Glomerulosclerosis FSGS and A-beta Pathways: Uptake and Degradation. The drugs Methylprednisolone and Methylprednisolone hemisuccinate have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and t cells, and related phenotype is renal/urinary system.

Sources

Related Diseases for Glomerular Disease

About this section

Diseases related to Glomerular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 337)
# Related Disease Score Top Affiliating Genes
1 membranoproliferative glomerulonephritis 31.8 NPHS1 CD79A ALB
2 iga nephropathy 1 31.6 NPHS2 NPHS1 CD79A ACE
3 familial nephrotic syndrome 31.2 NPHS2 NPHS1 CD2AP
4 nephrotic syndrome 31.1 NPHS2 NPHS1 CD2AP ALB ACE
5 denys-drash syndrome 31.1 NPHS2 NPHS1 CD2AP
6 nephrotic syndrome, type 1 31.0 NPHS2 NPHS1 CD2AP
7 frasier syndrome 31.0 NPHS2 NPHS1 CD2AP
8 focal segmental glomerulosclerosis 1 30.9 NPHS2 NPHS1 CD2AP
9 microvascular complications of diabetes 3 30.9 NPHS1 ALB ACE
10 membranous nephropathy 30.7 NPHS2 NPHS1 CD79A CD2AP ALB ACE
11 mesangial proliferative glomerulonephritis 30.7 CD79A CCL2
12 genetic steroid-resistant nephrotic syndrome 30.6 NPHS2 NPHS1 CD2AP
13 lipoid nephrosis 30.3 NPHS2 NPHS1 CD79A CD2AP CCL2 ALB
14 idiopathic nephrotic syndrome 30.3 NPHS2 ALB ACE
15 focal segmental glomerulosclerosis 2 30.3 NPHS2 NPHS1 CD2AP
16 chronic graft versus host disease 30.3 CD79A ALB
17 diffuse mesangial sclerosis 30.2 NPHS2 NPHS1
18 acute kidney tubular necrosis 30.2 ALB ACE
19 acute poststreptococcal glomerulonephritis 30.2 CD79A ALB
20 nephrotic syndrome, type 2 30.2 NPHS2 NPHS1
21 arteriolosclerosis 30.0 CD79A ALB
22 nail-patella syndrome 29.9 NPHS2 NPHS1 CD2AP
23 anuria 29.8 ALB ACE
24 iga glomerulonephritis 29.8 NPHS2 NPHS1 MIR30A CD79A ALB ACE
25 pierson syndrome 29.7 NPHS2 NPHS1 COL4A5
26 hypertensive nephropathy 29.6 AMBP ALB ACE
27 focal segmental glomerulosclerosis 29.5 NPHS2 NPHS1 COL4A5 CD2AP ALB ACE
28 glomerulonephritis 29.5 NPHS2 NPHS1 COL4A5 CD79A CCL2 ALB
29 goodpasture syndrome 29.5 NPHS1 COL4A5 ALB
30 end stage renal failure 29.5 NPHS2 NPHS1 COL4A5 ALB ACE
31 nephrosclerosis 29.4 NPHS2 NPHS1 CCL2 ACE
32 vesicoureteral reflux 1 29.3 AMBP ALB ACE
33 plasma cell neoplasm 29.3 CD79A ALB
34 acute proliferative glomerulonephritis 29.2 NPHS2 NPHS1 CCL2 ALB
35 autosomal dominant polycystic kidney disease 29.1 CCL2 ALB ACE
36 bacteriuria 29.1 CD79A CCL2
37 chronic kidney disease 28.6 NPHS2 NPHS1 COL4A5 CCL2 ALB ACE
38 kidney disease 28.0 NPHS2 NPHS1 COL4A5 CD79A CD2AP CCL2
39 hypertension, essential 26.9 NPHS2 NPHS1 COL4A5 CCL2 AMBP ALB
40 genetic glomerular disease 12.3
41 immunotactoid glomerulopathy 11.6
42 glomerulopathy with fibronectin deposits 2 11.6
43 fibrillary glomerulonephritis 11.6
44 immunotactoid or fibrillary glomerulopathy 11.4
45 loin pain hematuria syndrome 11.2
46 galloway-mowat syndrome 6 11.0
47 nephronophthisis 11.0
48 rapidly progressive glomerulonephritis 10.8
49 c3 glomerulopathy 10.8
50 systemic lupus erythematosus 10.7

Graphical network of the top 20 diseases related to Glomerular Disease:



Diseases related to Glomerular Disease
Sources

Symptoms & Phenotypes for Glomerular Disease

About this section

MGI Mouse Phenotypes related to Glomerular Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.23 ACE ALB CD2AP CD79A COL4A5 KLF15
Sources

Drugs & Therapeutics for Glomerular Disease

About this section

Drugs for Glomerular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
2
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
4 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
6
Atorvastatin Approved Phase 4 134523-00-5 60823
7
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
8
Losartan Approved Phase 4 114798-26-4 3961
9
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
10
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
11
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
12
Uric acid Investigational Phase 4 69-93-2 1175
13 Immunoglobulin A Phase 4
14 Cassava Phase 4
15 Methylprednisolone Acetate Phase 4
16 Cyclosporins Phase 4
17 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
18 Hypolipidemic Agents Phase 4
19 Anticholesteremic Agents Phase 4
20 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
21 Lipid Regulating Agents Phase 4
22 Protective Agents Phase 4
23 Antioxidants Phase 4
24 Hormones Phase 4
25 Hormone Antagonists Phase 4
26 Immunosuppressive Agents Phase 4
27 Immunologic Factors Phase 4
28 Pharmaceutical Solutions Phase 4
29 Adrenocorticotropic Hormone Phase 4
30 Melanocyte-Stimulating Hormones Phase 4
31 beta-endorphin Phase 4
32 Calcineurin Inhibitors Phase 4
33 Antihypertensive Agents Phase 4
34 Anti-Arrhythmia Agents Phase 4
35 Angiotensin II Type 1 Receptor Blockers Phase 4
36 Angiotensin Receptor Antagonists Phase 4
37 Giapreza Phase 4
38 Angiotensinogen Phase 4
39 Vasoconstrictor Agents Phase 4
40 Sodium Chloride Symporter Inhibitors Phase 4
41 Natriuretic Agents Phase 4
42 diuretics Phase 4
43
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
44
Epoprostenol Approved Phase 2, Phase 3 61849-14-7, 35121-78-9 5280427 5282411
45
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
46
Mycophenolic acid Approved Phase 3 24280-93-1 446541
47
Azathioprine Approved Phase 3 446-86-6 2265
48 Beraprost Investigational Phase 2, Phase 3 88430-50-6
49 Tezosentan Investigational Phase 2, Phase 3 180384-57-0
50 Dermatologic Agents Phase 3

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 Treatment of Nephrotic Syndrome Relapse With Low Steroid Dose Unknown status NCT02216747 Phase 4 prednisone 60 mg/meter square Body Surface Area;prednisone 45 mg;prednisone 30 mg
2 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
3 Study of Safety, Immunogenicity and Immunological Memory of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome Unknown status NCT01346007 Phase 4
4 The Renal Protective Effects of Low-dose and High-dose Atorvastatin in Patients With Glomerular Disease and Proteinuria: a Randomized Controlled Double Blinded Study Completed NCT00768638 Phase 4 Atorvastatin;Atorvastatin
5 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial Completed NCT02502071 Phase 4 sodium bicarbonate
6 A Multicenterer, Comparative Safety Andof ACTHar Gel Alone or in Cwith oe Urinary in Patients Positive Fibrillary Glomerulopathy Recruiting NCT04080076 Phase 4 Acthar 80 UNT/ML Injectable Solution;Tacrolimus capsule
7 Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome: a Randomized, Multicenter, Open-label, Parallel-arm Study Not yet recruiting NCT04048161 Phase 4 Tacrolimus;Mycophenolate Mofetil
8 Specific Blockage of Angiotensine 2 and Podocyturia in Glomerular Nephropathies With Hypertension and Proteinuria Suspended NCT00369538 Phase 4 losartan, hydrochlorothiazide;hydrochlorothiazide, losartan
9 Effect of Rituximab in Treatment of Primary Membranoproliferative Glomerulonephritis Unknown status NCT03180723 Phase 3 Rituximab;Cyclosporin
10 TRK-100STP PhaseIIb/III Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis) Completed NCT01090037 Phase 2, Phase 3 TRK-100STP high dose;TRK-100STP low dose;Placebo
11 The Use of Rituximab in the Treatment of Idiopathic Membranous Nephropathy Completed NCT00425217 Phase 2, Phase 3 Rituximab
12 A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy Active, not recruiting NCT03018535 Phase 3 Rituximab;Methylprednisolone;Cyclophosphamide
13 A Randomized, Multicenter Study to Assess the Efficacy on Diseases Activity of Enteric-coated Mycophenolate Sodium Versus Continuation of Azathioprine in Patients With Systemic Lupus Erythematosus on Azathioprine Maintenance Therapy. Terminated NCT00504244 Phase 3 switch to Myfortic;continuation of azathioprine
14 A Double Blind Clinical Trial to Examine the Renal Effects of an Angiotensin Converting Enzyme Inhibitor (Enalapril) in Adults With Chronic Kidney Disease of Uncertain Aetiology (CKDu) Unknown status NCT01624064 Phase 1, Phase 2 Enalapril;Calcium Supplement
15 TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis) Completed NCT02480751 Phase 2 Beraprost;Placebo
16 Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease Recruiting NCT03865407 Phase 2 Allopurinol
17 Rituximab From the First Episode of Minimal Change Nephrotic Syndrome for Preventing Relapse Risk in Adult Patients: a Multicenter Randomized Controlled Trial Not yet recruiting NCT03970577 Phase 2 Rituximab;Prednisone
18 A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VIS649 Administered Intravenously in Healthy Subjects Completed NCT03719443 Phase 1
19 Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis Completed NCT00275613 Phase 1 Rituximab
20 Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy Completed NCT01221181 Phase 1 Eculizumab
21 Pilot Study of Mycophenolate Mofetil in Congenital Uropathies Completed NCT00193635 Phase 1 mycophenolate mofetil
22 Clinical Significance of Assesment of Serum miRNA-30a in Childhood Nephrotic Syndrome Unknown status NCT03235128
23 Identification of Patients With High Probability of Not or Poorly Responding to Mycophenolate-mofetil (Cellcept®) or Mycophenolate-natrium (Myfortic®) Therapy Unknown status NCT00978965
24 Steroid Treatment of Childhood Idiopathic Nephrotic Syndrome: Epidemiology, Therapeutic Adequacy, Medium and Long Term Outcomes. A Prospective Observational Cohort Study. Unknown status NCT01386957
25 Interest to Perform a Renal Biopsy Early in the Course of the Henoch-Schoenlein Nephritis Unknown status NCT02811770
26 Pilot Study: Efficacy and Safety of Vitamin D Supplementation in Glomerular Disease Completed NCT01835639
27 Histological and Clinical Biomarkers to Predict the Progression of IgA Nephropathy Completed NCT02529722
28 Kidney Disease Biomarkers Completed NCT00255398
29 Lupus Nephritis: Role of Environmental and Occupational Exposures Completed NCT00342329
30 Prospective Evaluation of Albuminuria in HIV Positive Patients Completed NCT00524992
31 Correlation Between the Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma. Completed NCT01572857
32 Pathogenesis of Glomerulosclerosis Completed NCT00001392
33 Rituximab in the Treatment of Idiopathic Membranous Nephropathy Completed NCT00405340 Early Phase 1 Rituximab
34 Multicenter Prospective Cohort of Kidney Biopsy for Glomerular Disease Research Recruiting NCT03929887
35 Epigenetic Contribution to the Pathogenesis of Diabetic Nephropathy in Qatari Population Recruiting NCT02316522
36 Nephrologic Intervention in Patients Waiting for Cardiac Surgery Recruiting NCT02643745
37 Different Histopathological Patterns in Patients With HCV Nephropathy Not yet recruiting NCT03476031
38 Human Urine Sample Collection for Alport Nephropathy Biomarker Studies Terminated NCT01602835

Search NIH Clinical Center for Glomerular Disease

Sources

Genetic Tests for Glomerular Disease

About this section
Sources

Anatomical Context for Glomerular Disease

About this section

MalaCards organs/tissues related to Glomerular Disease:

40
Kidney, Endothelial, T Cells, Bone, Liver, Monocytes, Neutrophil
Sources

Publications for Glomerular Disease

About this section

Articles related to Glomerular Disease:

(show top 50) (show all 2860)
# Title Authors PMID Year
1
Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. 61 46
18776121 2008
2
Effects of Sustained-Release Beraprost in Patients With Primary Glomerular Disease or Nephrosclerosis: CASSIOPEIR Study Results. 61
31119846 2020
3
Recurrence of FSGS after Kidney Transplantation in Adults. 61
31974287 2020
4
Effect of the traditional Chinese medicine Qi Teng Xiao Zhuo granules on chronic glomerulonephritis rats studied by using long noncoding RNAs expression profiling. 61
31821871 2020
5
Acute and chronic glomerular damage is associated with reduced CD133 expression in urinary extracellular vesicles. 61
31869243 2020
6
Steroid-resistant nephrotic syndrome: pharmacogenetics and epigenetic points and views. 61
31847609 2020
7
Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial. 61
31907076 2020
8
Proteinuria-take a closer look! 61
31925536 2020
9
HIV-related nephropathy: new aspects of an old paradigm. 61
31939539 2020
10
Glomerular disease in children: when to biopsy. 61
31951262 2020
11
Podocyte autophagy is associated with foot process effacement and proteinuria in patients with minimal change nephrotic syndrome. 61
31978139 2020
12
Injured Podocytes Are Sensitized to Angiotensin II-Induced Calcium Signaling. 61
31924670 2020
13
Patterns in renal diseases diagnosed by kidney biopsy: a single-center experience. 61
31955562 2020
14
Mode of initial renal replacement therapy and transplant outcomes in the chronic kidney disease in children (CKiD) study. 61
31797095 2019
15
Tubular injury triggers podocyte dysfunction by β-catenin-driven release of MMP-7. 61
31743113 2019
16
Bone Health in Glomerular Kidney Disease. 61
31734906 2019
17
Indoxyl sulfate associates with cardiovascular phenotype in children with chronic kidney disease. 61
31428929 2019
18
Podocyte histone deacetylase activity inhibition as a therapeutic strategy for glomerular disease. 61
31759482 2019
19
Metabolic rewiring of the hypertensive kidney. 61
31822592 2019
20
Forward genetic screen in human podocytes identifies diphthamide biosynthesis genes as regulators of adhesion. 61
31566424 2019
21
The association of acute rejection vs recurrent glomerular disease with graft outcomes after kidney transplantation. 61
31630440 2019
22
Trends of renal diseases in Germany: review of a regional renal biopsy database from 1990 to 2013. 61
31808446 2019
23
A new mouse model of anti-GBM disease sheds light on maternal transfer of alloantibodies in glomerular disease. 61
31759484 2019
24
Complement and Complement Targeting Therapies in Glomerular Diseases. 61
31888179 2019
25
TRPC Channels in Proteinuric Kidney Diseases. 61
31877991 2019
26
Clinicopathological features in membranous nephropathy with cancer: A retrospective single-center study and literature review. 61
31617780 2019
27
Using Electronic Health Record Data to Rapidly Identify Children with Glomerular Disease for Clinical Research. 61
31732612 2019
28
Toxocariasis and nephrotic syndrome. 61
31929297 2019
29
Compositional alterations of gut microbiota in children with primary nephrotic syndrome after initial therapy. 61
31771550 2019
30
Diffuse membranoproliferative glomerulonephritis with focal sclerosis and renal amyloidosis in an adult male with autosomal dominant dystrophic epidermolysis bullosa: a case report. 61
31498016 2019
31
Occurrence, management and outcome of immune-complex glomerulonephritis in dogs with suspected glomerulopathy in the UK. 61
31512262 2019
32
Sonic hedgehog connects podocyte injury to mesangial activation and glomerulosclerosis. 61
31647783 2019
33
Low-dose corticosteroid and mycophenolate for primary treatment of minimal change disease. 61
31769845 2019
34
[A patient with rheumatoid arthritis presenting a nephrotic syndrome: A case report]. 61
31636048 2019
35
Epidemiology and Pathophysiology of Glomerular C4d Staining in Native Kidney Biopsies. 61
31890997 2019
36
Expanding the phenotype of COPA syndrome: a kindred with typical and atypical features. 61
30385646 2019
37
Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics. 61
31725919 2019
38
Clinical impact of repeat renal biopsies in patients with lupus nephritis: Renal biopsy is essential especially later in the course of the disease. 61
31782721 2019
39
Pathological spectrum of glomerular disease in patients with renal insufficiency: a single-center study in Northeastern China. 61
31198075 2019
40
Inhibition of the ERK1/2-mTORC1 axis ameliorates proteinuria and the fibrogenic action of transforming growth factor-β in Adriamycin-induced glomerulosclerosis. 61
31377057 2019
41
Incidence of initial renal replacement therapy over the course of kidney disease in children. 61
31595948 2019
42
Has The Time Arrived to Refine The Indications of Immunosuppressive Therapy and Prognosis in IgA Nephropathy? 61
31581654 2019
43
Recent advances in risk prediction, therapeutics and pathogenesis of IgA nephropathy. 61
31142099 2019
44
The Influence of a Nanopatterned Scaffold that Mimics Abnormal Renal Mesangial Matrix on Mesangial Cell Behavior. 61
31661773 2019
45
Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence. 61
31590268 2019
46
Rationale and Design for a Phase 1 Study of N-Acetylmannosamine for Primary Glomerular Diseases. 61
31701055 2019
47
From podocyte biology to novel cures for glomerular disease. 61
31420194 2019
48
Hemodialysis in children: how, when and why. 61
31630720 2019
49
Methods for Assessing Longitudinal Biomarkers of Time-to-Event Outcomes in CKD: A Simulation Study. 61
31416887 2019
50
Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method. 61
31551522 2019
Sources

Variations for Glomerular Disease

About this section

ClinVar genetic disease variations for Glomerular Disease:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 COL4A5 NM_033380.3(COL4A5):c.1871G>A (p.Gly624Asp)SNV Pathogenic 24455 rs104886142 X:107842023-107842023 X:108598793-108598793
2 COL4A3 NM_000091.4(COL4A3):c.2657-1G>TSNV Uncertain significance 397521 rs373324875 2:228148482-228148482 2:227283766-227283766
Sources

Expression for Glomerular Disease

About this section
Search GEO for disease gene expression data for Glomerular Disease.
Sources

Pathways for Glomerular Disease

About this section

Pathways related to Glomerular Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Primary Focal Segmental Glomerulosclerosis FSGS 1
10.79 NPHS2 NPHS1 COL4A5 CD2AP
2
A-beta Pathways: Uptake and Degradation 64
10.76 CCL2 ACE
3
Nephrin/Neph1 signaling in the kidney podocyte 1
10.55 NPHS2 NPHS1 CD2AP
4
Nephrin interactions 65
10.5 NPHS1 CD2AP
Sources

GO Terms for Glomerular Disease

About this section

Cellular components related to Glomerular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.63 NPHS2 NPHS1 CD2AP AMBP ALB ACE
2 extracellular space GO:0005615 9.43 MIR30A COL4A5 CCL2 AMBP ALB ACE
3 slit diaphragm GO:0036057 8.62 NPHS2 NPHS1

Biological processes related to Glomerular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 excretion GO:0007588 8.62 NPHS2 NPHS1
Sources

Sources for Glomerular Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....